A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT ID: NCT06966700
Last Updated: 2026-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
2400 participants
INTERVENTIONAL
2025-06-30
2034-12-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment
* Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone.
Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread.
The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy:
* Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy
* Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT04197687
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
NCT02685306
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
NCT03044730
Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
NCT06991790
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
NCT03106077
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sac-TMT
Participants receive sacituzumab tirumotecan intravenously (IV) at a dose of 4 mg/kg every 2 weeks (Q2W) + IV pembrolizumab 200 mg every 3 weeks (Q3W), for 12 weeks; then receive IV pembrolizumab 200 mg Q3W and IV carboplatin area under the curve (AUC) 1.5 + IV paclitaxel 80 mg/m\^2 once weekly, for 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant treatment of physician's choice (TPC) may be administered to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); capecitabine 1000-1250 mg/m\^2 oral twice daily on days 1-14 and 22-35 each cycle for 4 six-week cycles; or doxorubicin 60mg/m\^2 (or epirubicin 90 mg/m\^2) IV infusion Q3W/Q2W + cyclophosphamide 600 mg/m\^2 IV infusion Q3W/Q2W for 4 doses.
Sacituzumab tirumotecan
IV infusion
Pembrolizumab
IV infusion
Rescue Medication
Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).
Carboplatin
IV infusion
Paclitaxel
IV infusion
Doxorubicin
IV infusion
Epirubicin
IV infusion
Cyclophosphamide
IV infusion
Capecitabine
Oral tablet
Olaparib
Oral tablet
Chemotherapy
Participants receive IV carboplatin AUC 1.5 and paclitaxel 80 mg/m\^2 once weekly, alongside pembrolizumab 200 mg Q3W, for 6 weeks; then receive IV pembrolizumab 200 mg Q3W alongside IV cyclophosphamide 600 mg/m\^2 Q3W and either doxorubicin 60 mg/m\^2 Q3W or epirubicin 90 mg/m\^2 Q3W, for up to 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options are olaparib 300 mg oral BID for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); or capecitabine 1000-1250 mg/m\^2 oral BID on days 1-14 and 22-35 each cycle for 4 six-week cycles.
Pembrolizumab
IV infusion
Rescue Medication
Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).
Carboplatin
IV infusion
Paclitaxel
IV infusion
Doxorubicin
IV infusion
Epirubicin
IV infusion
Cyclophosphamide
IV infusion
Capecitabine
Oral tablet
Olaparib
Oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab tirumotecan
IV infusion
Pembrolizumab
IV infusion
Rescue Medication
Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).
Carboplatin
IV infusion
Paclitaxel
IV infusion
Doxorubicin
IV infusion
Epirubicin
IV infusion
Cyclophosphamide
IV infusion
Capecitabine
Oral tablet
Olaparib
Oral tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* cT1c, N1-N2
* cT2, N0-N2
* cT3, N0-N2
* cT4a-d, N0-N2
* The participant must have a centrally confirmed diagnosis of BC that is triple-negative or HR-low+/HER2- (defined as estrogen receptor (ER)-low+ expression in 1% to 10% cells and HER2-), as by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
* Provides a core needle biopsy from the primary breast tumor at screening to the central laboratory.
* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 28 days before treatment randomization.
* Demonstrates adequate organ function.
Exclusion Criteria
* Has received any prior treatment, including radiation, systemic therapy,and/or definitive surgery for currently diagnosed breast cancer
* Has undergone excisional biopsy of the primary tumor, axillary lymph node dissection, and/or axillary sentinel lymph node biopsy prior to study treatment.
* Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
* Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX- 40, CD137).
* Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC).
* Received prior treatment with a topoisomerase I inhibitor-containing ADC.
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
* Known additional malignancy that is progressing or has required active treatment within the past 5 years.
* Uncontrolled systemic disease.
* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner MD Anderson Cancer Center ( Site 0066)
Gilbert, Arizona, United States
Roy and Patricia Disney Family Cancer Center ( Site 0055)
Burbank, California, United States
Providence Medical Foundation ( Site 0080)
Fullerton, California, United States
Hoag Memorial Hospital Presbyterian ( Site 0010)
Newport Beach, California, United States
Helios Clinical Research ( Site 0061)
Whittier, California, United States
Saint Joseph Hospital ( Site 0062)
Denver, Colorado, United States
Intermountain Health St. Mary's Regional Hospital ( Site 0054)
Grand Junction, Colorado, United States
Florida Cancer Specialists - South ( Site 7004)
Fort Myers, Florida, United States
Bioresearch Partner ( Site 0072)
Hialeah, Florida, United States
Florida Cancer Specialists - North ( Site 7002)
St. Petersburg, Florida, United States
Fort Wayne Medical Oncology and Hematology ( Site 0084)
Fort Wayne, Indiana, United States
Franciscan Health ( Site 0077)
Indianapolis, Indiana, United States
Ochsner Clinic Foundation ( Site 0021)
New Orleans, Louisiana, United States
Louisiana State University Health Sciences Shreveport ( Site 0053)
Shreveport, Louisiana, United States
New England Cancer Specialists ( Site 0051)
Westbrook, Maine, United States
Mercy Medical Center - Baltimore ( Site 0015)
Baltimore, Maryland, United States
Washington University Siteman Cancer Center ( Site 0031)
St Louis, Missouri, United States
Cancer Partners of Nebraska ( Site 0068)
Lincoln, Nebraska, United States
Renown Regional Medical Center ( Site 0041)
Reno, Nevada, United States
Hackensack Univ Medical Center (HUMC) ( Site 0007)
Hackensack, New Jersey, United States
Rutgers Cancer Institute of New Jersey ( Site 0076)
New Brunswick, New Jersey, United States
Altru Health System ( Site 0057)
Grand Forks, North Dakota, United States
Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027)
Cincinnati, Ohio, United States
Avera McKennan Hospital ( Site 0002)
Sioux Falls, South Dakota, United States
Avera Cancer Institute - Yankton ( Site 0089)
Yankton, South Dakota, United States
Tennessee Cancer Specialists ( Site 7001)
Knoxville, Tennessee, United States
Nashville General Hospital ( Site 0017)
Nashville, Tennessee, United States
Hendrick Medical Center ( Site 0009)
Abilene, Texas, United States
JPS Oncology and Infusion Center ( Site 0083)
Fort Worth, Texas, United States
Kelsey Research Foundation ( Site 0042)
Houston, Texas, United States
Kelsey-Seybold Clinic ( Site 0088)
Houston, Texas, United States
Oncology Consultants P.A. ( Site 0073)
Houston, Texas, United States
Texas Oncology - San Antonio ( Site 8004)
San Antonio, Texas, United States
Intermountain Medical Center ( Site 0074)
Murray, Utah, United States
Bon Secours Cancer Institute at St. Francis ( Site 0048)
Midlothian, Virginia, United States
Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005)
Roanoke, Virginia, United States
Cancer Care Northwest ( Site 0003)
Spokane, Washington, United States
Northwest Medical Specialties, PLLC ( Site 0067)
Tacoma, Washington, United States
University of Wisconsin-Madison ( Site 0024)
Madison, Wisconsin, United States
Instituto de Investigaciones Clinicas Mar del Plata ( Site 6008)
Mar del Plata, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires-ginecology ( Site 6003)
Buenos Aires, Buenos Aires F.D., Argentina
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 6005)
Buenos Aires, Buenos Aires F.D., Argentina
Fundacion Ars Medica ( Site 6004)
San Salvador de Jujuy, Jujuy Province, Argentina
Sanatorio Parque ( Site 6002)
Rosario, Santa Fe Province, Argentina
Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L ( Site 6006)
San Miguel de Tucumán, Tucumán Province, Argentina
Sanatorio Finochietto ( Site 6007)
Buenos Aires, , Argentina
Sanatorio Allende - Nueva Córdoba ( Site 6000)
Córdoba, , Argentina
Sanatorio de la Cañada - Córdoba ( Site 6001)
Córdoba, , Argentina
Chris O'Brien Lifehouse ( Site 1206)
Camperdown, New South Wales, Australia
Monash Health ( Site 1201)
Clayton, Victoria, Australia
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman ( Site 3204)
Liège, Liege, Belgium
Jessa Ziekenhuis ( Site 3200)
Hasselt, Limburg, Belgium
AZORG Campus Aalst-Moorselbaan ( Site 3201)
Aalst, Oost-Vlaanderen, Belgium
UZ Gent ( Site 3202)
Ghent, Oost-Vlaanderen, Belgium
CHU UCL Namur/Site Sainte Elisabeth ( Site 3203)
Namur, , Belgium
PRONUTRIR ( Site 6120)
Fortaleza, Ceará, Brazil
Hospital Araújo Jorge ( Site 6100)
Goiânia, Goiás, Brazil
Liga Norte Riograndense Contra o Câncer ( Site 6111)
Natal, Rio Grande do Norte, Brazil
Associação Hospitalar Beneficente São Vicente de Paulo ( Site 6115)
Passo Fundo, Rio Grande do Sul, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 6102)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital São Lucas da PUCRS ( Site 6103)
Porto Alegre, Rio Grande do Sul, Brazil
Clínica de Oncologia Reichow ( Site 6112)
Blumenau, Santa Catarina, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 6108)
Barretos, São Paulo, Brazil
Hospital de Base de São José do Rio Preto ( Site 6101)
São José do Rio Preto, São Paulo, Brazil
INCA Hospital do Câncer III ( Site 6107)
Rio de Janeiro, , Brazil
NL Health Services ( Site 0232)
St. John's, Newfoundland and Labrador, Canada
Health Sciences North ( Site 0234)
Greater Sudbury, Ontario, Canada
Lakeridge Health ( Site 0225)
Oshawa, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0208)
Toronto, Ontario, Canada
Jewish General Hospital ( Site 0200)
Montreal, Quebec, Canada
CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0203)
Québec, Quebec, Canada
CIUSSS de l'Estrie-CHUS ( Site 0206)
Sherbrooke, Quebec, Canada
Anhui Provincial Cancer Hospital ( Site 2234)
Hefei, Anhui, China
Beijing Cancer Hospital ( Site 2201)
Beijing, Beijing Municipality, China
The First Affiliated hospital of Xiamen University-Breast Surgery ( Site 2224)
Xiamen, Fujian, China
Guangdong Maternity and Child Health Care Hospital ( Site 2251)
Guangzhou, Guangdong, China
Jiangmen Center Hospital ( Site 2243)
Jiangmen, Guangdong, China
Liuzhou People's Hospital ( Site 2259)
Liuchow, Guangxi, China
Guangxi Medical University Affiliated Tumor Hospital ( Site 2223)
Nanning, Guangxi, China
Harbin Medical University Cancer Hospital ( Site 2204)
Haerbin, Heilongjiang, China
Henan Cancer Hospital ( Site 2238)
Zhengzhou, Henan, China
Wuhan Union Hospital ( Site 2239)
Wuhan, Hubei, China
Xiangya Hospital of Central South University ( Site 2225)
Changsha, Hunan, China
Nanjing Drum Tower Hospital ( Site 2217)
Nanjing, Jiangsu, China
Jiangsu Province Hospital ( Site 2216)
Nanjing, Jiangsu, China
The Third Hospital Of Nanchang ( Site 2218)
Nanchang, Jiangxi, China
The First Hospital Of Jilin University ( Site 2207)
Changchun, Jilin, China
The First Affiliated Hospital of Xi'an Jiaotong University ( Site 2203)
Xi'an, Shaanxi, China
Jinan Central Hospital ( Site 2249)
Jinan, Shandong, China
Shandong Cancer Hospital ( Site 2205)
Jinan, Shandong, China
Fudan University Shanghai Cancer Center ( Site 2209)
Shanghai, Shanghai Municipality, China
Deyang City People's Hospital ( Site 2244)
Deyang, Sichuan, China
The Second People's Hospital of Neijiang ( Site 2242)
Neijiang, Sichuan, China
Xinjiang Medical University Cancer Hospital - Urumqi ( Site 2230)
Ürümqi, Xinjiang, China
Yunnan Province Cancer Hospital ( Site 2226)
Kunming, Yunnan, China
The Second Affiliated Hospital of Zhejiang University School of Medicine ( Site 2212)
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital ( Site 2211)
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital ( Site 2215)
Hangzhou, Zhejiang, China
Instituto de Cancerología-Oncology ( Site 6302)
Medellín, Antioquia, Colombia
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 6311)
Bogotá, Bogota D.C., Colombia
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 6309)
Bogotá, Bogota D.C., Colombia
IMAT S.A.S ( Site 6300)
Montería, Departamento de Córdoba, Colombia
Oncologos del Occidente ( Site 6303)
Pereira, Risaralda Department, Colombia
Fundación Valle del Lili ( Site 6308)
Cali, Valle del Cauca Department, Colombia
Oulun yliopistollinen sairaala ( Site 3603)
Oulu, North Ostrobothnia, Finland
Tampereen ylipistollinen sairaala ( Site 3601)
Tampere, Pirkanmaa, Finland
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 3600)
Helsinki, Uusimaa, Finland
Centre Georges Francois Leclerc ( Site 3902)
Dijon, Bourgogne-Franche-Comté, France
Centre de Cancerologie du Grand Montpellier ( Site 3910)
Montpellier, Herault, France
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 3900)
Rennes, Ille-et-Vilaine, France
CHU d'Amiens-Picardie - Hôpital Sud ( Site 3908)
Amiens, Somme, France
HENRI MONDOR HOSPITAL ( Site 3904)
Créteil, Val-de-Marne, France
MEDI-K ( Site 6400)
Guatemala City, , Guatemala
CELAN,S.A ( Site 6401)
Guatemala City, , Guatemala
INTEGRA Cancer Institute ( Site 6404)
Guatemala City, , Guatemala
Onco Go, S.A ( Site 6402)
Guatemala City, , Guatemala
Asociacion Española de Beneficencia ( Site 6403)
Guatemala City, , Guatemala
Hong Kong United Oncology Centre ( Site 1304)
Jordan, , Hong Kong
Queen Mary Hospital ( Site 1300)
Pokfulam, , Hong Kong
Prince of Wales Hospital ( Site 1301)
Shatin, , Hong Kong
Tuen Mun Hospital ( Site 1303)
Tuenmen, , Hong Kong
Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 4207)
Kecskemét, Bács-Kiskun county, Hungary
Rambam Health Care Campus ( Site 4400)
Haifa, , Israel
Meir Medical Center. ( Site 4403)
Kfar Saba, , Israel
Sheba Medical Center ( Site 4401)
Ramat Gan, , Israel
Yitzhak Shamir Medical Center. ( Site 4404)
Ẕerifin, , Israel
Nagoya City University Hospital ( Site 2310)
Nagoya, Aichi-ken, Japan
National Hospital Organization Hokkaido Cancer Center ( Site 2300)
Sapporo, Hokkaido, Japan
Kanagawa Cancer Center ( Site 2308)
Yokohama, Kanagawa, Japan
Mie University Hospital ( Site 2312)
Tsu, Mie-ken, Japan
Kansai Medical University Hospital ( Site 2317)
Hirakata, Osaka, Japan
Kindai University Hospital ( Site 2316)
Sakai, Osaka, Japan
The University of Osaka Hospital ( Site 2314)
Suita, Osaka, Japan
Shizuoka Cancer Center ( Site 2309)
Sunto-gun, Shizuoka, Japan
National Cancer Center Hospital ( Site 2305)
Chūō, Tokyo, Japan
Toranomon Hospital ( Site 2307)
Minato, Tokyo, Japan
Showa Medical University Hospital ( Site 2306)
Shinagawa, Tokyo, Japan
Akita University Hospital ( Site 2302)
Akita, , Japan
Chiba Cancer Center ( Site 2303)
Chiba, , Japan
Fukushima Medical University Hospital ( Site 2301)
Fukushima, , Japan
Hiroshima City Hiroshima Citizens Hospital ( Site 2318)
Hiroshima, , Japan
Kumamoto Shinto General Hospital ( Site 2322)
Kumamoto, , Japan
Kyoto University Hospital ( Site 2313)
Kyoto, , Japan
Nakagami Hospital ( Site 2323)
Okinawa, , Japan
National Hospital Organization Osaka National Hospital ( Site 2315)
Osaka, , Japan
Hospital Pulau Pinang ( Site 1502)
George Town, Pulau Pinang, Malaysia
National Cancer Institute ( Site 1501)
Putrajaya, Putrajaya, Malaysia
Sarawak General Hospital ( Site 1504)
Kuching, Sarawak, Malaysia
Pantai Hospital Kuala Lumpur ( Site 1500)
Kuala Lumpur, , Malaysia
Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 6605)
Concepción, Departamento de Junín, Peru
IPOR Instituto Peruano de Oncología & Radioterapia ( Site 6600)
Lima, , Peru
Oncosalud ( Site 6603)
Lima, , Peru
Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 4616)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Oddzial w Krakowie ( Site 4612)
Krakow, Lesser Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 4609)
Warsaw, Masovian Voivodeship, Poland
Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 4614)
Olsztyn, Warmian-Masurian Voivodeship, Poland
Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 4702)
Lisbon, Lisbon District, Portugal
Hospital de Cascais Doutor José de Almeida ( Site 4700)
Lisbon, , Portugal
National Cancer Centre Singapore ( Site 1700)
Singapore, Central Singapore, Singapore
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 4907)
Port Elizabeth, Eastern Cape, South Africa
Wits Clinical Research ( Site 4903)
Johannesburg, Gauteng, South Africa
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 4901)
Pretoria, Gauteng, South Africa
Sandton Oncology Medical Group (Pty) Ltd ( Site 4900)
Sandton, Gauteng, South Africa
Cancercare Rondebosch Oncology ( Site 4906)
Cape Town, Western Cape, South Africa
National Cancer Center ( Site 1800)
Goyang-si, Kyonggi-do, South Korea
Seoul National University Bundang Hospital ( Site 1801)
Kyonggi-do, Kyonggi-do, South Korea
Kyungpook National University Chilgok Hospital ( Site 1805)
Taegu, Taegu-Kwangyokshi, South Korea
Seoul National University Hospital ( Site 1806)
Seoul, , South Korea
Severance Hospital Yonsei University Health System ( Site 1804)
Seoul, , South Korea
Asan Medical Center ( Site 1803)
Seoul, , South Korea
Samsung Medical Center ( Site 1807)
Seoul, , South Korea
The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 1802)
Seoul, , South Korea
Institut Català d'Oncologia - L'Hospitalet ( Site 5001)
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital de Basurto ( Site 5007)
Bilbao, Bizkaia, Spain
Complejo asistencial universitario de Salamanca ( Site 5000)
Salamanca, Castille and León, Spain
HOSPITAL UNIVERSITARIO DE JAEN ( Site 5003)
Jaén, Jaen, Spain
CHUS - Hospital Clinico Universitario ( Site 5006)
Santiago de Compostela, La Coruna, Spain
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 5004)
Pozuelo de Alarcón, Madrid, Spain
Hospital General de Valencia ( Site 5008)
Valencia, Valenciana, Comunitat, Spain
Parc de Salut Mar - Hospital del Mar ( Site 5005)
Barcelona, , Spain
Hospital Beata María Ana ( Site 5010)
Madrid, , Spain
Hospital Universitario Virgen Macarena ( Site 5002)
Seville, , Spain
Skånes Universitetssjukhus Malmö ( Site 3802)
Malmo, Skåne County, Sweden
Karolinska Universitetssjukhuset Solna ( Site 3800)
Stockholm, Stockholm County, Sweden
Akademiska sjukhuset ( Site 3801)
Uppsala, Uppsala County, Sweden
Södra Älvsborgs Sjukhus Borås ( Site 3804)
Borås, Västra Götaland County, Sweden
Taichung Veterans General Hospital ( Site 1904)
Taichung, , Taiwan
National Taiwan University Hospital ( Site 1900)
Taipei, , Taiwan
MacKay Memorial Hospital ( Site 1903)
Taipei, , Taiwan
National Taiwan University Cancer Center (NTUCC) ( Site 1901)
Taipei, , Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 1906)
Taoyuan District, , Taiwan
Faculty of Medicine Siriraj Hospital ( Site 2000)
Bangkok, Bangkok, Thailand
COMMUNAL NONPROFIT ENTERPRISE "CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 5207)
Cherkasy, Cherkasy Oblast, Ukraine
Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 5208)
Chernivtsi, Chernivetska Oblast, Ukraine
CNCE Precarpathian Clinical Oncologic Center ( Site 5201)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
CNE Regional clinical oncology center of Kirovograd regional Council ( Site 5203)
Kropyvnytsky, Kirovohrad Oblast, Ukraine
Shalimov Institute of Surgery and Transplantation ( Site 5210)
Kyiv, , Ukraine
Ninewells Hospital and Medical School ( Site 5300)
Dundee, Dundee City, United Kingdom
Huddersfield Royal Infirmary ( Site 5313)
Huddersfield, England, United Kingdom
St Bartholomew s Hospital ( Site 5302)
London, London, City of, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1316-7898
Identifier Type: REGISTRY
Identifier Source: secondary_id
2024-520190-12-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
jRCT2031250231
Identifier Type: REGISTRY
Identifier Source: secondary_id
2870-032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.